Sunesis Pharmaceuticals (NASDAQ: SNSS) was upgraded by equities research analysts at RBC Capital (NYSE: RY) from a “sector perform” rating to an “outperform” rating in a research note issued to investors on Tuesday. The firm currently has a $5.00 price target on the stock, up from their previous price target of $3.00.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cantor Fitzgerald initiated coverage on shares of Sunesis Pharmaceuticals in a research note to investors on Thursday, April 12nd. They set a “buy” rating and a $6.00 price target on the stock. Analysts at Canaccord Genuity initiated coverage on shares of Sunesis Pharmaceuticals in a research note to investors on Tuesday, March 6th. They set a “buy” rating and a $4.00 price target on the stock.
Shares of Sunesis Pharmaceuticals traded down 0.64% during mid-day trading on Tuesday, hitting $3.09. Sunesis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $3.19. The company’s market cap is $145.0 million.
Sunesis Pharmaceuticals last announced its earnings results on Tuesday, May 15th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.12. On average, analysts predict that Sunesis Pharmaceuticals will post $-0.20 earnings per share next quarter.
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers.